<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40388776</article-id><article-id pub-id-type="pmc">PMC12091595</article-id>
<article-id pub-id-type="publisher-id">MD-D-24-14674</article-id><article-id pub-id-type="art-access-id">00057</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000042451</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version><article-categories><subj-group subj-group-type="heading"><subject>3400</subject></subj-group><subj-group><subject>Research Article</subject><subject>Clinical Case Report</subject></subj-group></article-categories><title-group><article-title>The necessity for prompt identification of Sj&#x000f6;gren syndrome in instances of unexplained heart failure: A case report</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0003-6041-1020</contrib-id><name><surname>Wu</surname><given-names>Jiao</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0007-0559-7431</contrib-id><name><surname>Zhang</surname><given-names>Hongcai</given-names></name><degrees>MM</degrees><xref rid="aff2" ref-type="aff">b</xref><xref rid="c1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Wen</given-names></name><degrees>MM</degrees><email>1131649799@g9.com</email><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Mingjun</given-names></name><degrees>MM</degrees><email>824776452@qq.com</email><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Nie</surname><given-names>Qian</given-names></name><degrees>MM</degrees><email>113685849@qq.com</email><xref rid="aff2" ref-type="aff">b</xref></contrib><aff id="aff1"><label>a</label>Eye School of Chengdu University of TCM, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China</aff><aff id="aff2"><label>b</label>Department of Cardiology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.</aff></contrib-group><author-notes><corresp id="c1"><label>*</label>Correspondence: Hongcai Zhang, Department of Cardiology, Hospital of Chengdu University of Traditional Chinese Medicine, No.39-41, Shijiqiao Road, Jinniu District, Chengdu, Sichuan Province, China (e-mail: <email xlink:href="qwerrtyui_@qq.com">qwerrtyui_@qq.com</email>).</corresp></author-notes><pub-date pub-type="collection"><day>16</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>16</day><month>5</month><year>2025</year></pub-date><volume>104</volume><issue>20</issue><elocation-id>e42451</elocation-id><history><date date-type="received"><day>26</day><month>11</month><year>2024</year></date><date date-type="received"><day>19</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>25</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CCBY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="medi-104-e42451.pdf"/><abstract><sec><title>Rationale:</title><p>Sj&#x000f6;gren&#x02019;s syndrome (SS) is a highly phenotypically diverse autoimmune disorder. It has been reported that 30% to 40% of patients with SS experience systemic complications, including peripheral neuropathies, interstitial lung disease, interstitial nephritis, and lymphoma. To date, SS presenting with heart failure (HF) as the primary manifestation remains exceedingly rare.</p></sec><sec><title>Patient concerns:</title><p>We report presents a 70-year-old female patient, devoid of any cardiovascular risk factors, who experienced recurrent episodes of HF.</p></sec><sec><title>Diagnoses:</title><p>During the course of treatment, SS was suspected based on her medical history. This suspicion was subsequently confirmed through elevated serum autoimmune antibody levels and a labial gland biopsy.</p></sec><sec><title>Interventions:</title><p>The implementation of standard HF management in conjunction with an immunosuppressive regimen.</p></sec><sec><title>Outcomes:</title><p>At the one-year follow-up, the patient had not been readmitted for HF.</p></sec><sec><title>Lessons:</title><p>This case underscores the critical importance of early identification of HF attributable to SS and highlights the efficacy of combining immunosuppressive therapy with conventional HF treatment as the optimal approach for managing such cases.</p></sec></abstract><kwd-group><kwd>antinuclear antibodies</kwd><kwd>heart failure</kwd><kwd>immunosuppressants</kwd><kwd>primary</kwd><kwd>Sj&#x000f6;gren&#x02019;s syndrome</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>
1. Introduction</title><p>Sj&#x000f6;gren&#x02019;s syndrome (SS) is a multifaceted, chronic autoimmune disorder affecting multiple systems, primarily characterized by lymphocytic infiltration of exocrine glands, notably the salivary and lacrimal glands, leading to symptoms such as xerostomia, xerophthalmia, fatigue, and arthralgia.<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> SS is a phenotypically varied autoimmune disorder that can be divided to primary Sj&#x000f6;gren&#x02019;s syndrome (pSS) and secondary SS, which is associated with other connective tissue disease, such as rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis in some instances. A global epidemiological study has indicated that the prevalence of SS ranges from 0.01% to 0.05%, with a marked predominance in females aged 30 to 50 years, reflected in a male-to-female ratio of approximately 1:14.<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup> In the majority of instances, SS primarily affects the exocrine glands. Nevertheless, approximately 30% to 40% of patients may present with extraglandular manifestations, including those affecting the thyroid, lungs, gastrointestinal tract, hematological system, kidneys, skin, and both central and peripheral nervous systems.<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> Notably, while cardiac involvement in SS can manifest as conduction block, autoimmune myocarditis, cardiomyopathy, and pericardial effusion.<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup> SS presenting with heart failure (HF) as the primary manifestation remains exceedingly rare, although a case of secondary SS complicated by HF was first documented in 2021.<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup> But up to date, there are extremely few studies described the eventual heart failure caused by the pSS in the literature.</p><p>In this report, we present a case involving a 70-year-old female patient who experienced recurrent episodes of unexplained HF as the primary clinical manifestation, despite having no prior history of cardiovascular disease. Ultimately, she was diagnosed with pSS-induced HF according to the American College of Rheumatology and the European Alliance of Associations for Rheumatology (ACR/EULAR)-approved diagnostic criteria of pSS.<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> The implementation of standard HF management in conjunction with an immunosuppressive regimen resulted in a favorable clinical outcome for the patient. This case underscores the critical importance of early identification of HF attributable to pSS and highlights the efficacy of combining immunosuppressive therapy with conventional HF treatment as the optimal approach for managing such cases.</p></sec><sec sec-type="cases"><title>
2. Case presentation</title><p>A 70-year-old female patient were admitted to hospital for a 6-year history of respiratory distress, bilateral lower-limb edema persisting for 12 months, and aggravation of chest tightness and dyspnea for 10 days. In 2018&#x0ff0c;she visited to a local hospital due to respiratory system symptom, especially cough, chest tightness, shortness of breath, and dyspnea. She had a history of hypothyroidism but no reported history of hypertension, diabetes, or coronary artery disease. A chest computed tomography scan revealed interstitial pneumonia, but she refused further thorough clinical examination and systematic treatment at the time. Subsequently, she has had recurrent respiratory system symptoms between 2018 and 2023. During the past 12 months&#x0ff0c;the patient condition aggravated further, and she presented with paroxysmal nocturnal dyspnea, bilateral lower limb depression and edema, which suggested HF symptoms.</p><p>After admission, a physical examination of the patient were recorded as follows: a body temperature of 37.4&#x000b0;C, a heart rate of 112 beats/min, and a blood pressure of 80/47&#x02009;mm Hg. A thorough physical examination revealed positive liver neck reflux, pronounced wet murmurs in both lungs, an enlarged cardiac silhouette, and distant heart sounds. Furthermore, significant edema was observed in both lower extremities. Then, we performed a urgent hematologic review for the patient, which included routine blood test, myocardial enzyme spectrum, C-reactive protein, procalcitonin, liver and kidney function tests, electrolyte assessment, and biochemistry tests (Table <xref rid="T1" ref-type="table">1</xref>). Through laboratory analysis, it was determined that the patient exhibited a significant increase in white blood cell count (14.32&#x02005;&#x000d7;&#x02005;10<sup>9</sup>/L), alongside elevated cardiac biomarkers, including cardiac troponin I (0.7&#x02009;ng/mL; reference value, &#x0003c;0.01&#x02009;ng/mL), creatine kinase-isoenzyme (30 U/L), and N-terminal pro-brain natriuretic peptide (25,420 pg/mL). Additionally, the patient demonstrated signs of hepatic dysfunction, as evidenced by elevated serum levels of hyaluronic acid (234.20&#x02009;ng/mL), laminin (53.11&#x02009;ng/mL), type IV collagen (50.94&#x02009;ng/mL), glycocholic acid hydrate (5.24 &#x000b5;g/mL), and the N-terminal peptide of type III procollagen (153.80&#x02009;ng/mL). Furthermore, thyroid dysfunction was indicated by an increased thyroid stimulating hormone level (12.44 &#x000b5;IU/mL) and altered thyroid hormone concentration (64.88 nmol/L). Notably, the patient renal function remains within normal parameters. Electrocardiogram findings indicated sinus tachycardia with low voltage across all leads (Fig. <xref rid="F1" ref-type="fig">1</xref>A). The most recent chest computed tomography scan reveals evidence of chronic bronchitis, bilateral pulmonary interstitial fibrosis with superimposed infection, and mild to moderate pleural effusion (Fig. <xref rid="F1" ref-type="fig">1</xref>B). Furthermore, the cardiac echocardiogram results showed that the patient left ventricular ejection fraction was 45%, accompanied by moderate to large pericardial effusion, cardiac dilation, heart enlargement, and pulmonary hypertension (Fig. <xref rid="F1" ref-type="fig">1</xref>C). Thus, the patient was diagnosed with acute HF, hypothyroidism, and pulmonary infection.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Laboratory tests of the patient.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Hematological tests</th><th align="center" rowspan="1" colspan="1">Results of the patient</th><th align="center" rowspan="1" colspan="1">Reference value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Routine blood test</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;White blood cell count (&#x000d7;10<sup>9</sup>/L)</td><td align="center" rowspan="1" colspan="1">14.32</td><td align="center" rowspan="1" colspan="1">3.5&#x02013;9.5</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Neutrophil count (&#x000d7;10<sup>9/</sup>L)</td><td align="center" rowspan="1" colspan="1">9.14</td><td align="center" rowspan="1" colspan="1">1.8&#x02013;6.3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lymphocyte count (&#x000d7;10<sup>9</sup>/L)</td><td align="center" rowspan="1" colspan="1">3.81</td><td align="center" rowspan="1" colspan="1">1.1&#x02013;3.2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Monocyte count (&#x000d7;10<sup>9</sup>/L)</td><td align="center" rowspan="1" colspan="1">1.31</td><td align="center" rowspan="1" colspan="1">0.1&#x02013;0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hemoglobin (g/L)</td><td align="center" rowspan="1" colspan="1">141</td><td align="center" rowspan="1" colspan="1">130&#x02013;175</td></tr><tr><td align="left" rowspan="1" colspan="1">Thyroid function test</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Thyroid stimulating hormone (uTU/mL)</td><td align="center" rowspan="1" colspan="1">12.44</td><td align="center" rowspan="1" colspan="1">0.27&#x02013;5.00</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Thyroid hormones (nmol/L)</td><td align="center" rowspan="1" colspan="1">64.88</td><td align="center" rowspan="1" colspan="1">66&#x02013;181</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Triiodothyronine (nmol/L)</td><td align="center" rowspan="1" colspan="1">0.96</td><td align="center" rowspan="1" colspan="1">1.3&#x02013;3.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Free thyroxine (pmol/L)</td><td align="center" rowspan="1" colspan="1">14.71</td><td align="center" rowspan="1" colspan="1">12&#x02013;22</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Thyroglobulin (ng/mL)</td><td align="center" rowspan="1" colspan="1">35.86</td><td align="center" rowspan="1" colspan="1">3.5&#x02013;77</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Thyroglobulin antibodies</td><td align="center" rowspan="1" colspan="1">0.59</td><td align="center" rowspan="1" colspan="1">2.1&#x02013;4.0 weakly positive;<break/>&#x0003e;4 positive</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Antithyroid peroxidase antibody (IU/mL)</td><td align="center" rowspan="1" colspan="1">12.87</td><td align="center" rowspan="1" colspan="1">&#x0003c;34</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Thyrotropin receptor antibody (IU/L)</td><td align="center" rowspan="1" colspan="1">1.11</td><td align="center" rowspan="1" colspan="1">&#x0003c;1.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Indicators of hepaticfibrosis</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hyaluronicacid (ng/mL)</td><td align="center" rowspan="1" colspan="1">234.20</td><td align="center" rowspan="1" colspan="1">0&#x02013;100</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Laminin (ng/mL)</td><td align="center" rowspan="1" colspan="1">53.11</td><td align="center" rowspan="1" colspan="1">0.51&#x02013;50</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Collagen type IV (ng/mL)</td><td align="center" rowspan="1" colspan="1">50.940</td><td align="center" rowspan="1" colspan="1">0.021&#x02013;30</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Cholyglycine (ug/mL)</td><td align="center" rowspan="1" colspan="1">5.24</td><td align="center" rowspan="1" colspan="1">0&#x02013;2.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial enzyme spectrum</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;cTNI (ng/mL)</td><td align="center" rowspan="1" colspan="1">0.7</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;CK-MB (U/L)</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NT-proBNP (pg/mL)</td><td align="center" rowspan="1" colspan="1">25,420</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Liver function tests</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Total protein (g/L)</td><td align="center" rowspan="1" colspan="1">68.9</td><td align="center" rowspan="1" colspan="1">65&#x02013;85</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Albumin (g/L)</td><td align="center" rowspan="1" colspan="1">30.7</td><td align="center" rowspan="1" colspan="1">40&#x02013;55</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Globulin (g/L)</td><td align="center" rowspan="1" colspan="1">38.2</td><td align="center" rowspan="1" colspan="1">20&#x02013;40</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Globulin ratio</td><td align="center" rowspan="1" colspan="1">0.8</td><td align="center" rowspan="1" colspan="1">1.2&#x02013;2.4</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Alanine aminotransferase (U/L)</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">7&#x02013;40</td></tr><tr><td align="left" rowspan="1" colspan="1">Kidney function tests</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Urea (U/L)</td><td align="center" rowspan="1" colspan="1">6.21</td><td align="center" rowspan="1" colspan="1">3.1&#x02013;8.8</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Creatinine (&#x003bc;mol/L)</td><td align="center" rowspan="1" colspan="1">68.5</td><td align="center" rowspan="1" colspan="1">41&#x02013;81</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Uric acid (&#x003bc;mol/L)</td><td align="center" rowspan="1" colspan="1">425</td><td align="center" rowspan="1" colspan="1">142&#x02013;339</td></tr><tr><td align="left" rowspan="1" colspan="1">Electrolyte</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Potassium (mmol/L)</td><td align="center" rowspan="1" colspan="1">3.64</td><td align="center" rowspan="1" colspan="1">3.5&#x02013;5.3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Sodium (mmol/L)</td><td align="center" rowspan="1" colspan="1">135.9</td><td align="center" rowspan="1" colspan="1">137&#x02013;147</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Chlorine (mmol/L)</td><td align="center" rowspan="1" colspan="1">104.7</td><td align="center" rowspan="1" colspan="1">99&#x02013;110</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Calcium (mmol/L)</td><td align="center" rowspan="1" colspan="1">2.06</td><td align="center" rowspan="1" colspan="1">2.11&#x02013;2.52</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Magnesium (mmol/L)</td><td align="center" rowspan="1" colspan="1">0.81</td><td align="center" rowspan="1" colspan="1">0.75&#x02013;1.02</td></tr><tr><td align="left" rowspan="1" colspan="1">Autoimmune antibody spectrum</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Antinuclear antibodies (ANA)</td><td align="center" rowspan="1" colspan="1">Positive</td><td align="center" rowspan="1" colspan="1">Negative (&#x0003c;100)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Anti-double-stranded DNA antibody</td><td align="center" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">Negative (&#x0003c;10)</td></tr><tr><td align="left" rowspan="1" colspan="1">ANA (karyotype)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Nuclear particle type</td><td align="center" rowspan="1" colspan="1">1:3200 (+++)</td><td align="center" rowspan="1" colspan="1">&#x0003c;1:00</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Cytoplasmic granule type</td><td align="center" rowspan="1" colspan="1">&#x0003e;1000 (++)</td><td align="center" rowspan="1" colspan="1">&#x0003c;1:00</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-nRNP antibody</td><td align="center" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">Negative</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-SM antibody</td><td align="center" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">Negative</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-SSA antibody</td><td align="center" rowspan="1" colspan="1">Positive</td><td align="center" rowspan="1" colspan="1">Negative</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-SSB antibody</td><td align="center" rowspan="1" colspan="1">Weakly Positive</td><td align="center" rowspan="1" colspan="1">Negative</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-ScL-70</td><td align="center" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">Negative</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-Jo-1</td><td align="center" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">Negative</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>ANA = antinuclear antibodies, cTNI = cardiac troponin I, CK-MB = creatine kinase-isoenzyme, DNA = deoxyribonucleic acid, nRNP = nuclear ribonucleoprotein, NT-proBNP = N-terminal pro-brain natriuretic peptide, SM = smith, SSA = Sj&#x000f6;gren's syndrome A, SSB = Sj&#x000f6;gren's syndrome B.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F1"><label>Figure 1.</label><caption><p>Examination results of the patient. (A) ECG shows sinus tachycardia with low voltage. (B) Chest CT indicates bilateral pulmonary interstitial fibrosis with superimposed infection. (C) Echocardiogram reveals a 45% left ventricular ejection fraction, moderate to large pericardial effusion, cardiac dilation, and pulmonary hypertension. (D) Labial gland biopsy shows small salivary gland tissues with significant lymphocyte and plasma cell infiltration. CT = computed tomography, ECG = electrocardiogram.</p></caption><graphic xlink:href="medi-104-e42451-g001" position="float"/></fig><p>Subsequently, we administered a comprehensive treatment regimen to the patient, which included cefoperazone/sulbactam for the management of pulmonary infection, recombinant human brain natriuretic peptide to promote vasodilation and decrease cardiac workload, furosemide for diuresis, sacubitril/valsartan to reduce cardiac oxygen consumption, dapagliflozin to inhibit ventricular remodeling, spironolactone to prevent myocardial fibrosis and hypertrophy, and levosimendan to enhance cardiac contractility and facilitate vasodilation. Despite the absence of cardiovascular risk factors, the patient exhibited significantly elevated troponin levels and nonspecific ischemic changes on the electrocardiogram. To elucidate the etiology of the HF, coronary angiography was conducted once the patient condition stabilized to determine if coronary heart disease was present. The angiographic findings revealed dual vessel disease, characterized by 50% stenosis in both the right anterior descending and right distal coronary arteries; hence, no additional intervention was deemed necessary.</p><p>In view of the absence of known cardiovascular risk factors and an additional past medical history, but similar HF symptoms appeared repeatedly and not been effectively managed in the patient. In order to identify the etiology of HF, we once again inquiring about the detailed additional physical symptoms. Notably, the patient reported a 20-year history of dry eye syndrome, for which artificial tears were regularly employed, alongside symptoms of xerostomia. Consequently, we hypothesized the potential presence of SS. To substantiate this hypothesis, we firstly conducted an comprehensive analysis of the autoimmune antibody spectrum. The findings, and the results revealed the presence of ANA with a titer of 1:3200 (+++), HX &#x0003e;1:1000 (++), and positive results for both anti-SS-A and anti-SS-B antibodies (Table <xref rid="T1" ref-type="table">1</xref>). Based on this finding, it was decided to proceed with a labial gland biopsy after taking the patient&#x02019; consent. Subsequent pathological findings of labial gland biopsy revealed small salivary gland tissues from the lower lip exhibiting interstitial infiltration by multifocal lymphocytes and plasma cells, with a lymphocyte density exceeding 50 per mm<sup>2</sup> (Fig. <xref rid="F1" ref-type="fig">1</xref>D). According to the ACR/EULAR-approved diagnostic criteria of pSS,<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> the patient meets the inclusion criteria and does not have any of the conditions listed as exclusion criteria, so she finally diagnosed with pSS (Table <xref rid="T2" ref-type="table">2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>The diagnosis of pSS of the patient according to ACR/EULAR-approved criteria.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Item</th><th align="center" rowspan="1" colspan="1">Weight/score</th><th align="center" rowspan="1" colspan="1">Patient score</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Labial salivary gland with focal lymphocytic sialadenitis and focus score of $1 foci/4&#x02009;mm<sup>2</sup></td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-SSA/Ro positive</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">
<bold>3</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-SSA/Ro positive ocular staining score&#x02005;&#x02265;&#x02005;5 (or van Bijsterveld score&#x02005;&#x02265;4) in at least 1 eye</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Not be determined</td></tr><tr><td align="left" rowspan="1" colspan="1">Schirmer test&#x02005;&#x02264;5&#x02009;mm/5&#x02009;min in at least 1 eye</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Not be determined</td></tr><tr><td align="left" rowspan="1" colspan="1">Unstimulated whole saliva flow rate&#x02005;&#x02264;0.1&#x02009;mL/min</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Not be determined</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>ACR/EULAR = American College of Rheumatology and the European Alliance of Associations for Rheumatology, pSS = primary Sj&#x000f6;gren&#x02019;s syndrome, SSA = Sj&#x000f6;gren's syndrome A.</p></fn></table-wrap-foot></table-wrap><p>Correspondingly, the treatment regimen was adjusted to include the immunosuppressant hydroxychloroquine and total glucosides of paeony capsules. Following discharge, the patient underwent ongoing treatment, which included hydroxychloroquine 20&#x02009;mg once daily, Baishao capsules 20&#x02009;mg once daily, furosemide 20&#x02009;mg once daily, spironolactone 20&#x02009;mg once daily, bisoprolol 5&#x02009;mg once daily, valsartan 100&#x02009;mg twice daily, dapagliflozin 10&#x02009;mg once daily, and levosimendan 5&#x02009;mg once daily. Throughout the one-year follow-up period, the symptoms of HF were effectively relieved, with no reported instances of readmission attributable to HF.</p></sec><sec sec-type="discussion"><title>
3. Discussion</title><p>SS is a systemic disease characterized by heterogeneous manifestations and the potential to cause multiorgan lesions, particularly affecting the salivary and lacrimal glands. Nearly all patients experience xerophthalmia and xerostomia, with data from a cohort of over 6000 patients indicating that 92% and 94% developed xerophthalmia and xerostomia, respectively.<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup> In addition to glandular symptoms, SS frequently presents with systemic manifestations. A multicenter study comprising 395 patients diagnosed with SS indicated that 30% of the cohort presented with systemic manifestations, including arthralgia or nonerosive arthritis (45%), pulmonary fibrosis (53%), interstitial lung disease (20%), peripheral nervous system symptoms (17%), cutaneous vasculitis (13%), and renal involvement such as tubulointerstitial nephritis and glomerulonephritis (10%).<sup>[<xref rid="R8" ref-type="bibr">8</xref>&#x02013;<xref rid="R13" ref-type="bibr">13</xref>]</sup> Consequently, the European Union of Rheumatology Associations (EULAR) formulated the EULAR SS Disease Activity Index to evaluate disease severity. This index encompasses 12 distinct domains: structural, lymphadenopathy, glandular, joint, skin, pulmonary, renal, muscular, peripheral nervous system, central nervous system, hematological, and biological.<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup> While the EULAR SS Disease Activity Index does not account for cardiovascular manifestations, a growing body of research suggests potential cardiac involvement in association with SS.<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> Numerous studies have indicated that patients with SS exhibit elevated serum lipid levels, a higher incidence of atherosclerosis, and an increased risk of cardiovascular events compared to the general population.<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup> For example, a study by Zhang identified a higher incidence of pulmonary hypertension in patients with SS.<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup> Additionally, another study found that patients with SS are at an increased risk of subclinical atherosclerosis compared to healthy individuals.</p><p>To comprehensively assess the impact of SS on cardiovascular risk factors, various surrogate outcome indices have indicated that patients with SS exhibit increased carotid intima-media thickness,<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup> valve regurgitation and augmented left ventricular mass,<sup>[<xref rid="R19" ref-type="bibr">19</xref>]</sup> pulmonary hypertension,<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup> as well as systolic dysfunction and reduced coronary reserve.<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup> These findings suggest that SS adversely affects cardiac structure and function. Although these manifestations are uncommon, failure to promptly identify them may result in missed or incorrect diagnoses within this patient population. The pathways through which SS contributes to HF encompass autoimmunity and persistent inflammatory processes. It is well-documented that immune complexes can cause damage to vascular endothelial cells,<sup>[<xref rid="R22" ref-type="bibr">22</xref>]</sup> subsequently contributing to the development of atherosclerosis. Clinical investigations have demonstrated increased levels of serum Ro/SS-A antibodies and rheumatoid factors in individuals with SS.<sup>[<xref rid="R23" ref-type="bibr">23</xref>]</sup> Furthermore, anti-Ro/SS-A and anti-La/SS-B antibodies have been linked to congenital heart block in neonates<sup>[<xref rid="R24" ref-type="bibr">24</xref>]</sup>; however, this correlation has not been substantiated in adult populations.</p><p>Several studies have demonstrated that adult patients with SS often exhibit prolonged P&#x02013;R intervals, indicating a potential link to conduction system defects.<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup> Additionally, the chronic inflammatory state associated with SS is known to induce the production of various proinflammatory cytokines, such as interleukin (IL)-6, IL-8, and tumor necrosis factor alpha, which can result in myocardial damage and alterations in cardiac structure and wall thickness.<sup>[<xref rid="R26" ref-type="bibr">26</xref>]</sup> Moreover, these proinflammatory cytokines may expedite the progression of atherosclerosis and contribute to the development of arrhythmias.</p><p>In this case study, a 70-year-old female patient, initially devoid of cardiovascular risk factors, presented with interstitial pneumonia and subsequently developed HF with preserved ejection fraction, leading to multiple hospital admissions over the past year. During the current hospitalization, she was additionally diagnosed with pulmonary hypertension and hypothyroidism. A comprehensive medical history indicated that the patient had experienced prolonged symptoms of xerostomia and xerophthalmia. Subsequent diagnostic evaluations, encompassing the Schirmer test, autoantibody profiling, and labial salivary gland biopsy, yielded positive findings consistent with the 2016 ACR/EULAR classification criteria for primary SS. Upon confirmation of the diagnosis, immunosuppressive therapy was initiated in conjunction with standard HF management, resulting in marked clinical improvements. A one-year follow-up revealed no additional hospitalizations due to HF. Consequently, we propose that the patient HF, interstitial pneumonia, pulmonary hypertension, and hypothyroidism may be associated with SS.</p><p>Traditionally, HF has been predominantly linked to ischemic cardiomyopathy, myocarditis, valvular heart disease, and hypertension, with comparatively limited attention given to autoimmune disorders, particularly SS. In this instance, prior therapeutic interventions concentrated exclusively on alleviating HF symptoms without addressing the underlying etiology, resulting in recurrent symptoms and misdiagnosis. This scenario often occurs due to the relatively nascent and underdeveloped status of rheumatology within the broader field of internal medicine, as numerous county-level and certain tertiary hospitals lack dedicated rheumatology departments or specialists. Furthermore, the insufficient understanding of SS among non-rheumatology specialists can result in misdiagnosis, particularly when the initial nonspecific symptoms are mistakenly attributed to menopause or diabetes-related conditions. Although cardiovascular manifestations of SS are infrequent, failure to detect them promptly may lead to missed or incorrect diagnoses within this patient population, potentially culminating in severe cardiovascular events.</p><p>This case underscores the critical importance of recognizing the systemic manifestations of SS and the necessity of conducting comprehensive patient histories and analyses in clinical practice. In instances of unexplained HF, it is imperative to adopt a proactive approach in identifying underlying etiologies to prevent reliance solely on symptomatic treatment. We propose the incorporation of autoantibody screening into the standard diagnostic protocol for unexplained HF to mitigate the risk of misdiagnosis.</p></sec><sec><title>
4. Conclusion</title><p>In conclusion, this study suggests that the diagnosis and management of unexplained HF should adopt a holistic approach that transcends the isolated examination of individual factors. Considering that HF constitutes the terminal stage of various cardiac pathologies, its management should not be restricted to mere symptomatic relief. Instead, it is crucial to actively identify and address the underlying etiologies to achieve more effective therapeutic outcomes. In instances of unexplained and recurrent HF, there is a pronounced need to identify the underlying autoimmune diseases it&#x02019;s sugge, such as pSS, as early as possible and highlights the efficacy of combining immunosuppressive therapy with conventional HF treatment as the optimal approach for managing such cases.</p></sec><sec><title>Acknowledgments</title><p>We thank the patient for her collaboration.</p></sec><sec><title>Author contributions</title><p><bold>Conceptualization:</bold> Hongcai Zhang.</p><p><bold>Investigation:</bold> Hongcai Zhang.</p><p><bold>Writing &#x02013; original draft:</bold> Jiao Wu, Wen Xie, Mingjun Han, Qian Nie.</p><p><bold>Writing &#x02013; review &#x00026; editing:</bold> Hongcai Zhang, Wen Xie, Mingjun Han, Qian Nie.</p></sec></body><back><fn-group><fn fn-type="abbr"><p>
<def-list><title>Abbreviations:</title><def-item><term>EULAR</term><def><p>European Union of Rheumatology Associations</p></def></def-item><def-item><term>HF</term><def><p>heart failure</p></def></def-item><def-item><term>pSS</term><def><p>primary Sj&#x000f6;gren&#x02019;s syndrome</p></def></def-item><def-item><term>SS</term><def><p>Sj&#x000f6;gren&#x02019;s syndrome.</p></def></def-item></def-list>
</p></fn></fn-group><fn-group><fn fn-type="other"><p>Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p></fn><fn fn-type="COI-statement"><p>The authors have no funding and conflicts of interest to disclose.</p></fn><fn fn-type="other"><p>Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.</p></fn><fn fn-type="other"><p>How to cite this article: Wu J, Zhang H, Xie W, Han M, Nie Q. The necessity for prompt identification of Sj&#x000f6;gren syndrome in instances of unexplained heart failure: A case report. Medicine 2025;104:20(e42451).</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldini</surname><given-names>C</given-names></name><name><surname>Fulvio</surname><given-names>G</given-names></name><name><surname>La Rocca</surname><given-names>G</given-names></name><name><surname>Ferro</surname><given-names>F</given-names></name></person-group>. <article-title>Update on the pathophysiology and treatment of primary Sj&#x000f6;gren syndrome.</article-title>
<source>Nat Rev Rheumatol</source>. <year>2024</year>;<volume>20</volume>:<fpage>473</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">38982205</pub-id>
</mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beydon</surname><given-names>M</given-names></name><name><surname>McCoy</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>Y</given-names></name><name><surname>Sumida</surname><given-names>T</given-names></name><name><surname>Mariette</surname><given-names>X</given-names></name><name><surname>Seror</surname><given-names>R</given-names></name></person-group>. <article-title>Epidemiology of Sj&#x000f6;gren syndrome.</article-title>
<source>Nat Rev Rheumatol</source>. <year>2024</year>;<volume>20</volume>:<fpage>158</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">38110617</pub-id>
</mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maleki-Fischbach</surname><given-names>M</given-names></name><name><surname>Kastsianok</surname><given-names>L</given-names></name><name><surname>Koslow</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>ED</given-names></name></person-group>. <article-title>Manifestations and management of Sj&#x000f6;gren&#x02019;s disease.</article-title>
<source>Arthritis Res Ther</source>. <year>2024</year>;<volume>26</volume>:<fpage>43</fpage>.<pub-id pub-id-type="pmid">38331820</pub-id>
</mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrukh</surname><given-names>L</given-names></name><name><surname>Mumtaz</surname><given-names>A</given-names></name><name><surname>Wajid</surname><given-names>S</given-names></name><name><surname>Waqar</surname><given-names>HH</given-names></name><name><surname>Peredo-Wende</surname><given-names>R</given-names></name></person-group>. <article-title>Cardiac manifestations of Sjogren&#x02019;s syndrome: a review of literature.</article-title>
<source>Cureus</source>. <year>2023</year>;<volume>15</volume>:<fpage>e41002</fpage>.<pub-id pub-id-type="pmid">37503463</pub-id>
</mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Kong</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Hao</surname><given-names>S</given-names></name></person-group>. <article-title>First report of rheumatoid arthritis and secondary Sj&#x000f6;gren&#x02019;s syndrome complicated with heart failure.</article-title>
<source>Clin Case Rep</source>. <year>2021</year>;<volume>9</volume>:<fpage>e04581</fpage>.<pub-id pub-id-type="pmid">34401161</pub-id>
</mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiboski</surname><given-names>CH</given-names></name><name><surname>Shiboski</surname><given-names>SC</given-names></name><name><surname>Seror</surname><given-names>R</given-names></name><etal/></person-group>; <collab>International Sj&#x000f6;gren's Syndrome Criteria Working Group</collab>. <article-title>2016 American College of Rheumatology/European league against rheumatism classification criteria for primary Sj&#x000f6;gren&#x02019;s syndrome: a consensus and data-driven methodology involving three international patient cohorts.</article-title>
<source>Arthritis Rheumatol</source>. <year>2017</year>;<volume>69</volume>:<fpage>35</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">27785888</pub-id>
</mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez</surname><given-names>MF</given-names></name><name><surname>Asnal</surname><given-names>C</given-names></name><name><surname>Gobbi</surname><given-names>CA</given-names></name><etal/></person-group>. <article-title>Primary Sj&#x000f6;gren syndrome and development of another autoimmune rheumatic disease during the follow-up.</article-title>
<source>Adv Rheumatol</source>. <year>2022</year>;<volume>62</volume>:<fpage>19</fpage>.<pub-id pub-id-type="pmid">35672809</pub-id>
</mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name></person-group>. <article-title>Update on disease pathogenesis, diagnosis, and management of primary Sj&#x000f6;gren&#x02019;s syndrome.</article-title>
<source>Int J Rheum Dis</source>. <year>2020</year>;<volume>23</volume>:<fpage>723</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">32297483</pub-id>
</mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Ferrada</surname><given-names>MA</given-names></name><name><surname>Hasni</surname><given-names>SA</given-names></name></person-group>. <article-title>Pulmonary manifestations of primary Sj&#x000f6;gren&#x02019;s syndrome: underlying immunological mechanisms, clinical presentation, and management.</article-title>
<source>Front Immunol</source>. <year>2019</year>;<volume>10</volume>:<fpage>1327</fpage>.<pub-id pub-id-type="pmid">31249572</pub-id>
</mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Xin</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Interstitial lung disease in primary Sj&#x000f6;gren&#x02019;s syndrome.</article-title>
<source>BMC Pulm Med</source>. <year>2022</year>;<volume>22</volume>:<fpage>73</fpage>.<pub-id pub-id-type="pmid">35220958</pub-id>
</mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liampas</surname><given-names>A</given-names></name><name><surname>Parperis</surname><given-names>K</given-names></name><name><surname>Erotocritou</surname><given-names>MF</given-names></name><etal/></person-group>. <article-title>Primary Sj&#x000f6;gren syndrome-related peripheral neuropathy: a systematic review and meta-analysis.</article-title>
<source>Eur J Neurol</source>. <year>2023</year>;<volume>30</volume>:<fpage>255</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">36086910</pub-id>
</mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popescu</surname><given-names>A</given-names></name><name><surname>Hickernell</surname><given-names>J</given-names></name><name><surname>Paulson</surname><given-names>A</given-names></name><name><surname>Aouhab</surname><given-names>Z</given-names></name></person-group>. <article-title>Neurological and psychiatric clinical manifestations of Sj&#x000f6;gren syndrome.</article-title>
<source>Curr Neurol Neurosci Rep</source>. <year>2024</year>;<volume>24</volume>:<fpage>293</fpage>&#x02013;<lpage>301</lpage>.<pub-id pub-id-type="pmid">38981949</pub-id>
</mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aiyegbusi</surname><given-names>O</given-names></name><name><surname>McGregor</surname><given-names>L</given-names></name><name><surname>McGeoch</surname><given-names>L</given-names></name><name><surname>Kipgen</surname><given-names>D</given-names></name><name><surname>Geddes</surname><given-names>CC</given-names></name><name><surname>Stevens</surname><given-names>KI</given-names></name></person-group>. <article-title>Renal disease in primary Sj&#x000f6;gren&#x02019;s syndrome.</article-title>
<source>Rheumatol Ther</source>. <year>2021</year>;<volume>8</volume>:<fpage>63</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">33367966</pub-id>
</mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>EJ</given-names></name><name><surname>Benjamin</surname><given-names>S</given-names></name><name><surname>Bombardieri</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>British Society for Rheumatology guideline on management of adult and juvenile onset Sj&#x000f6;gren disease.</article-title>
<source>Rheumatology (Oxford)</source>. <year>2025</year>;<volume>64</volume>:<fpage>409</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">38621708</pub-id>
</mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casian</surname><given-names>M</given-names></name><name><surname>Jurcut</surname><given-names>C</given-names></name><name><surname>Dima</surname><given-names>A</given-names></name><name><surname>Mihai</surname><given-names>A</given-names></name><name><surname>Stanciu</surname><given-names>S</given-names></name><name><surname>Jurcut</surname><given-names>R</given-names></name></person-group>. <article-title>Cardiovascular disease in primary Sj&#x000f6;gren&#x02019;s syndrome: raising clinicians&#x02019; awareness.</article-title>
<source>Front Immunol</source>. <year>2022</year>;<volume>13</volume>:<fpage>865373</fpage>.<pub-id pub-id-type="pmid">35757738</pub-id>
</mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atzeni</surname><given-names>F</given-names></name><name><surname>Gozza</surname><given-names>F</given-names></name><name><surname>Cafaro</surname><given-names>G</given-names></name><name><surname>Perricone</surname><given-names>C</given-names></name><name><surname>Bartoloni</surname><given-names>E</given-names></name></person-group>. <article-title>Cardiovascular involvement in Sj&#x000f6;gren&#x02019;s syndrome.</article-title>
<source>Front Immunol</source>. <year>2022</year>;<volume>13</volume>:<fpage>879516</fpage>.<pub-id pub-id-type="pmid">35634284</pub-id>
</mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Characteristics and risk factors for pulmonary arterial hypertension associated with primary Sj&#x000f6;gren&#x02019;s syndrome: 15 new cases from a single center.</article-title>
<source>Int J Rheum Dis</source>. <year>2019</year>;<volume>22</volume>:<fpage>1775</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">31368254</pub-id>
</mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karakasis</surname><given-names>P</given-names></name><name><surname>Patoulias</surname><given-names>D</given-names></name><name><surname>Pamporis</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Risk of subclinical atherosclerosis in primary Sjogren&#x02019;s syndrome: a systematic review and meta-analysis.</article-title>
<source>Eur J Intern Med</source>. <year>2024</year>;<volume>122</volume>:<fpage>93</fpage>&#x02013;<lpage>101</lpage>.<pub-id pub-id-type="pmid">37977997</pub-id>
</mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vassiliou</surname><given-names>VA</given-names></name><name><surname>Moyssakis</surname><given-names>I</given-names></name><name><surname>Boki</surname><given-names>KA</given-names></name><name><surname>Moutsopoulos</surname><given-names>HM</given-names></name></person-group>. <article-title>Is the heart affected in primary Sj&#x000f6;gren&#x02019;s syndrome? An echocardiographic study.</article-title>
<source>Clin Exp Rheumatol</source>. <year>2008</year>;<volume>26</volume>:<fpage>109</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">18328155</pub-id>
</mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duarte</surname><given-names>F</given-names></name><name><surname>Oliveira</surname><given-names>L</given-names></name><name><surname>Fontes</surname><given-names>T</given-names></name><name><surname>Ramos</surname><given-names>S</given-names></name><name><surname>Dourado</surname><given-names>R</given-names></name><name><surname>Martins</surname><given-names>D</given-names></name></person-group>. <article-title>Chronic constrictive pericarditis: a rare cardiac involvement in primary Sj&#x000f6;gren&#x02019;s syndrome.</article-title>
<source>BMC Cardiovasc Disord</source>. <year>2023</year>;<volume>23</volume>:<fpage>471</fpage>.<pub-id pub-id-type="pmid">37730569</pub-id>
</mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atzeni</surname><given-names>F</given-names></name><name><surname>Sarzi-Puttini</surname><given-names>P</given-names></name><name><surname>Signorello</surname><given-names>MC</given-names></name><etal/></person-group>. <article-title>New parameters for identifying subclinical atherosclerosis in patients with primary Sj&#x000f6;gren&#x02019;s syndrome: a pilot study.</article-title>
<source>Clin Exp Rheumatol</source>. <year>2014</year>;<volume>32</volume>:<fpage>361</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">24565029</pub-id>
</mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name></person-group>. <article-title>A review of the mechanism of vascular endothelial injury in immunoglobulin A vasculitis.</article-title>
<source>Front Physiol</source>. <year>2022</year>;<volume>13</volume>:<fpage>833954</fpage>.<pub-id pub-id-type="pmid">35370802</pub-id>
</mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma&#x0015b;li&#x00144;ska</surname><given-names>M</given-names></name><name><surname>Ma&#x00144;czak</surname><given-names>M</given-names></name><name><surname>Kwiatkowska</surname><given-names>B</given-names></name><name><surname>Ramsperger</surname><given-names>V</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Suresh</surname><given-names>L</given-names></name></person-group>. <article-title>IgA immunoglobulin isotype of rheumatoid factor in primary Sj&#x000f6;gren&#x02019;s syndrome.</article-title>
<source>Rheumatol Int</source>. <year>2021</year>;<volume>41</volume>:<fpage>643</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">33496802</pub-id>
</mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagliya</surname><given-names>D</given-names></name><name><surname>Castellano</surname><given-names>C</given-names></name><name><surname>Demory</surname><given-names>ML</given-names></name><name><surname>Kesselman</surname><given-names>MM</given-names></name></person-group>. <article-title>Sjogren&#x02019;s antibodies and neonatal lupus: a scoping review.</article-title>
<source>Cureus</source>. <year>2024</year>;<volume>16</volume>:<fpage>e62528</fpage>.<pub-id pub-id-type="pmid">39022488</pub-id>
</mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tam</surname><given-names>WK</given-names></name><name><surname>Hsu</surname><given-names>HC</given-names></name><name><surname>Hsieh</surname><given-names>MH</given-names></name><name><surname>Yeh</surname><given-names>JS</given-names></name><name><surname>Tam</surname><given-names>WC</given-names></name></person-group>. <article-title>Association of Anti-Ro/Sj&#x000f6;gren&#x02019;s syndrome type A antibodies and complete atrioventricular block in an adult with Sj&#x000f6;gren&#x02019;s syndrome.</article-title>
<source>Arch Rheumatol</source>. <year>2018</year>;<volume>33</volume>:<fpage>225</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">30207577</pub-id>
</mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariette</surname><given-names>X</given-names></name></person-group>. <article-title>Sj&#x000f6;gren&#x02019;s disease: from pathophysiology to treatment.</article-title>
<source>Biol Aujourdhui</source>. <year>2024</year>;<volume>218</volume>:<fpage>1</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">39007771</pub-id>
</mixed-citation></ref></ref-list></back></article>